---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-030865"
form_type: "8-K"
ticker: "IMDX"
cik: "0001642380"
company_name: "Insight Molecular Diagnostics Inc."
filed_at: "2024-08-09T23:59:59+00:00"
generated_at: "2026-05-31T10:24:18.720654+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Oncocyte enters $7.5M ATM with Needham, terminates prior $50M BTIG ATM

## Summary
- Enters Sales Agreement with Needham & Company for up to $7.5M of common stock at-the-market.
- Terminates prior ATM agreement with BTIG, LLC dated June 11, 2021 for up to $50M.
- Company may sell shares from time to time; Needham receives 3.0% commission on gross proceeds.
- Net proceeds intended for working capital and general corporate purposes.
- Placement shares registered under S-3 effective August 7, 2024.

## SEC filing metadata
- accession: 0001493152-24-030865
- form_type: 8-K
- ticker: IMDX
- cik: 0001642380
- company_name: Insight Molecular Diagnostics Inc.
- filed_at: 2024-08-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 1.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1642380/000149315224030865/0001493152-24-030865-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1642380/000149315224030865/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-030865
- JSON: https://secwatch.observer/filing/0001493152-24-030865.json
- Plain text: https://secwatch.observer/filing/0001493152-24-030865.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.